China pharma crackdown leads to flu vaccine shortage

Financial Times

26 November 2018 - Scarcity highlights lack of staff at regulator to inspect and approve vaccines.

Stricter inspections of Chinese vaccine manufacturers have caused a shortage of flu vaccines, raised the risks of widespread infections and highlighted the lack of staff at the country’s top pharmaceutical regulator.

China’s drug administration has required vaccine manufacturers to undergo on-site inspections after it was discovered in July that two Chinese companies had sold hundreds of thousands of substandard rabies and diphtheria, pertussis and tetanus vaccines.

Read Financial Times article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Regulation , Vaccine , Supply , China